Bayer's 95% Surge Faces Critical Legal and Earnings Test

Bayer shares up 95% face pivotal U.S. Supreme Court hearing on $7.25B glyphosate settlement, AGM, and Q1 results. Analysts weigh legal risks against strong pharma pipeline.

Shares in Bayer AG have soared nearly 95% from their April 2025 low, but the coming weeks present a decisive test. The stock’s remarkable run, which has lifted it to around €41, now confronts a dense calendar of legal and corporate events that will shape its near-term trajectory.

Central to investor concerns is a pivotal U.S. Supreme Court hearing scheduled for April 27. The court will review the preliminary approval of a $7.25 billion settlement intended to resolve existing and future lawsuits linking glyphosate to non-Hodgkin lymphoma. Claimants retain the right to opt out until June 4. For Bayer’s management, which has pinpointed 2027 as a potential turning point for financial recovery, a favorable ruling is crucial.

The legal drama unfolds alongside significant corporate dates. On April 24, the company holds its Annual General Meeting as a virtual event. Shareholders will vote on a proposed dividend of €0.11 per share for 2025 and approve changes to the supervisory board. Members Paul Achleitner and Colleen Goggins are stepping down, with nominations for OMV CEO Alfred Stern and Marcel Smits to succeed them, marking a notable reshuffle of the oversight body.

Financial clarity arrives on May 12 with the release of first-quarter 2026 results. Consensus estimates point to full-year earnings per share of approximately €4.29. Analysts will scrutinize the operational health of the business, particularly any macroeconomic headwinds impacting the agricultural division and the performance of key pharmaceutical products.

It is the pharma pipeline that provides the fundamental optimism underpinning analyst views. At a recent media day, pharmaceuticals head Stefan Oelrich outlined a concrete growth path, targeting mid-single-digit growth from 2027 onward and an operating margin around 30% by 2030. Products like Kerendia and Nubeqa are exceeding market expectations, while recent approval for the contrast agent Gadoquatrane in Japan and upcoming launches for Asundexian and Lynkuet promise future contributions.

This operational strength contrasts with ongoing financial pressures. Bayer anticipates a negative free cash flow for 2026, weighed down by litigation payouts. However, net debt stood at €29.8 billion at the end of 2025, an 8.5% reduction from the prior year. For the full year, the company targets currency-adjusted sales of €45-47 billion and EBITDA before special items of €9.6-10.1 billion.

Diverging analyst opinions reflect the complex balance of risks and opportunities. UBS strategist Matthew Weston reaffirms a "Buy" rating with a €52 price target, implying roughly 30% upside from current levels. He sees the stock’s position about 17% below its February high as an entry point. Conversely, DZ Bank recently shifted its stance from "Sell" to "Hold," raising its fair value estimate to €44. While not a bullish call, this upgrade signals a belief that the worst fears may already be reflected in the share price.

The outcome of the Supreme Court hearing and the subsequent quarterly report will likely determine whether the stock’s impressive recovery can sustain its momentum or faces a period of consolidation.